MELBOURNE, Australia and SAN FRANCISCO, March 02, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing ...

Emrusolmin is expected to improve symptoms of MSA by targeting alpha synuclein oligomers. The Food and Drug Administration (FDA) has granted Fast Track designation to emrusolmin (TEV-56286) for the ...

Phase 1b data on Lu AF28996, an investigational treatment for people with advanced Parkinson’s disease, to be presented at the 2026 AD/PD™ Conference·     Data evaluated safety, tolerability, ...

MELBOURNE, Australia and SAN FRANCISCO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing ...

Currently no disease-modifying or neuroprotective treatments exist for MSA, nor are there effective medications to treat the cerebellar ataxia in MSA-C or the parkinsonian features in MSA-P. Physical ...

Theravance Biopharma, Inc. (NASDAQ: TBPH) today announced the launch of “Power in the Periphery,” a new disease education campaign for healthcare professionals (HCPs) to raise awareness and deepen ...

- Data Presented at the International Congress of Parkinson’s Disease and Movement Disorders - The posters presented from Alterity’s bioMUSE study address the need for incorporating biomarkers as a ...

Early one morning, while checking on a slumbering patient at the Center for Sleep Medicine, Erik St. Louis, M.D., noticed something peculiar. The patient, a woman in her early 60's, had started ...

– Company is advancing ATH434 in late-stage clinical development for Multiple System Atrophy, a rapidly progressive neurodegenerative disease with no approved therapies – MELBOURNE, Australia and SAN ...

– Company is advancing ATH434 in late-stage clinical development for Multiple System Atrophy, a rapidly progressive neurodegenerative disease with no approved therapies – MSA is a progressive ...